Reducing the Harms of Nonclinical Psychedelics Use Through a Peer-Support Telephone Helpline

Earlier research indicates that psychedelic-assisted therapy (PAT) delivered in clinical settings includes multiple safeguards — medical and psychological screening, preparatory sessions, supervised dosing, and postdosing integration — which aim to maximise therapeutic benefit and reduce risk. By contrast, many people now use psychedelics outside clinical settings where those protections are absent. The extracted text notes rising nonclinical use in recent years, citing survey data that show increased past-year use among young adults and middle-aged adults, and highlights that harms from nonclinical use tend to be psychological (for example, distress, panic, or risky behaviour during so-called "bad trips") rather than toxicological in nature. This study sets out to examine whether a peer-support telephone helpline can reduce risks associated with nonclinical psychedelics use. Specifically, Pleet and colleagues piloted an existing peer-support helpline to determine whether conversations with trained volunteers de-escalated callers in distress and might avert emergency service use or other harms in naturalistic psychedelic contexts.

The investigators conducted a pilot, descriptive analysis using routinely collected, anonymous data from a psychedelic helpline operated by the nonprofit Fireside Project. The study period covered April 2021 to September 2022, and the University of California, San Francisco Institutional Review Board reviewed the work and deemed participant consent unnecessary because the data were anonymous (IRB no. 21-34162). Fireside Project offers free peer support during and after psychedelic experiences; volunteers receive a 50-hour training. The helpline is publicised via social and traditional media. Two data sources were analysed: an anonymous postcall survey texted to callers 24 hours after conversations, and call logs that peer-support specialists complete after each call. Peer-support specialists were instructed to ask only rapport-building and need-directed questions, so call logs reflect information volunteered by callers rather than a structured clinical interview. The authors analysed descriptive outcomes from these two sources. The text reports counts and percentages from the postcall survey and from the call logs (for example, social context, emotional content, and mention of underlying psychiatric conditions). The extracted text does not describe inferential statistical methods, hypothesis testing, or linkage of survey and call-log records, and it reports that the two data systems could not be linked.

During the study window, Fireside Project sent 4,047 postcall surveys and completed 4,047 call logs. Of the surveys sent, 848 were returned, a response rate of 20.9%. Postcall survey findings: Among the 848 respondents, 106 callers (12.5%) indicated that if not for their helpline conversation they might have called 9-1-1; 92 callers (10.8%) said they might have gone to an emergency room; and 249 callers (29.3%) reported they might have been physically or emotionally harmed had they not spoken with a peer-support specialist. For the subsample of 259 respondents who contacted the helpline to discuss past psychedelic experiences, 172 callers (66.4%) reported that the conversation de-escalated them from psychological distress. Within this subsample, 60 callers (23.2%) indicated they may have been physically or emotionally harmed without the call; 16 callers (6.1%) said they may have called 9-1-1; and 14 callers (5.4%) said they may have gone to the emergency room. Call-log findings: The call logs show that 3,386 callers contacted the helpline to discuss current or past psychedelic experiences and reported a range of difficult emotions, with "Fear," "Anxiety," "Confusion," and "Overwhelm" listed as distress-specific options. Among the 1,630 call logs for callers who were in the midst of a psychedelic experience, 650 callers (39.9%) reported taking the psychedelic alone; of these 650, 501 callers (77.0%) were at home and 28 callers (4.3%) were outdoors in nature. The logs also indicate that 909 of the 3,386 callers (27.4%) who discussed current or past experiences mentioned an underlying psychiatric condition. The extracted text refers to figures for further breakdowns but the numeric details reported above are those provided in the prose.

Pleet and colleagues interpret these descriptive results as preliminary evidence that access to a peer-support psychedelic helpline may reduce harms associated with nonclinical use. The investigators argue that helpline conversations appeared to de-escalate callers in psychological distress and that some callers reported they might otherwise have sought emergency services or experienced physical or emotional harm. In this framing, a psychedelic helpline could help fill a gap left by the absence of clinical safeguards in naturalistic settings and might offset some burden on emergency medical services. The authors position these findings against broader trends of increasing nonclinical psychedelics use and note an ethical imperative to develop responsible, scalable supports for people using psychedelics outside clinical contexts. They are cautious about generalisability and list several limitations. Callers were self-selecting and therefore may not represent all people who use psychedelics; the postcall survey had a 20.9% response rate; call logs reflect information volunteered to peer-support specialists rather than systematic ascertainment; call logs were completed by peers rather than clinicians, limiting the validity of reported psychiatric conditions; and free-text explanations in surveys were infrequent, constraining qualitative understanding of respondents' reasons. Finally, the two data systems could not be linked, preventing matched analyses of individual callers' survey and call-log data. Taken together, the authors suggest more research is needed but conclude that these early, descriptive data indicate a helpline model warrants further evaluation as a harm-reduction strategy for nonclinical psychedelics use.